Category Archives: Biotechnology

Marc Beer Gets a New Executive Role at LumeN XT

Marc Beer has been striving to revolutionize the world’s biotechnology and pharmaceutical industries for over 25 years. The expert has managed many top pharmaceutical companies, and he has started and developed some of the most successful biotechnology companies.

On April 2019, LumeN XT, a prominent manufacturer of surgical devices appointed Marc as the chairperson of its board. LumeNXT’s CEO said that the new brain would help them improve profitability, as well as help them develop and launch new surgical products that would streamline surgical operations.

At present, LumeN XT stands as the leading manufacturer of inexpensive surgical devices that improve surgical precision, minimize surgical invasiveness, as well as speed up various surgical procedures.

After the announcement, Marc Beer said that he was pleased to start his new role at the leading manufacturer of surgical devices. “I am pleased to join LumeNXT’s team of medical engineers. I will cooperate with the team to help LumeNXT develop more proprietary technologies to enhance the precision and safety of surgical procedures,” said Mr. Marc Beer.

Why did LumeN XT select Beer as the most suitable person to chair its board? In line with Paul Rhyne, a senior administrator at LumeN XT, Marc Beer had developed and exhibited exemplary skills in managing several companies in America’s healthcare industry.

“Marc Beer has sailed multiple organizations through different growth phases. He has a clean record in starting pharmaceutical companies and growing them to the industry’s upper locus. We believe that he will help LumeN XT to achieve its goals,” added Paul Rhyne.

At present, Marc Beer manages Renovia, Inc., a pharmaceutical start-up that develops therapeutic devices used to improve the living standards of people living with pelvic floor disorders. Already, the company has released several FDA approved methods that have improved the diagnosis and treatment of various pelvic floor disorders. Marc Beer launched the pharmaceutical startup in 2016.

Before moving to Renovia, Marc Beer served on the board of Minerva Neurosciences, a senior executive at Good Start Genetics, and a Board Member of Mass Life Science. He helped the companies to develop and launch new product lines, as well as improve their operations. Learn more: https://www.linkedin.com/in/marcbeer

Marc Beer: Investing in Biotechnology Companies to Improve

Women’s health worldwide received a boost after Renovia Inc. raised $10 million from venture debt and $32 million from a Series B round of funding. The funds raised will be directed towards developing products for diagnosing and treating pelvic disorders which affect more than 250 million women globally.

 

To raise the mentioned funds, the medtech company called on the services of Ascension Ventures and Perceptive Advisors based in Missouri and New York respectively. The Longwood Fund was one of the earliest investors in Renovia Inc. The investment firm focuses on healthcare companies and also joined the Series B round.

 

Based in Boston, Renovia Inc. is looking to develop and test another four diagnostic and therapeutic devices in addition to a new generation of the Leva device. Leva, the company’s first product, was approved by the FDA in April 2018.

 

In a statement, the CEO of Renovia Inc. said he was happy to have found support in leading healthcare investors interested in treating and improving the lives of women affected by pelvic floor disorders such as urinary incontinence.

 

He added that Renovia Inc. customers would now benefit from new treatment options once the company combines its proprietary and innovative form factors and sensor technologies with a digital platform. The digital platform would eventually lower healthcare costs in the long term since it would drive in-depth knowledge and understanding of pelvic floor disorders.

 

Marc Beer has been working with the development and commercialization of pharmaceutical and biotechnology diagnostics and devices for more than two decades. He is the Co-founder, Chairman, and CEO of Renovia Inc.

 

Before co-founding Renovia Inc., he worked with companies such as ViaCell and Genzyme. At ViaCell Marc Beer was the company’s Founding CEO. Under his leadership for seven years, the firm expanded to more than 300 employees before going public. PerkinElmer eventually purchased the company. ViaCell is a biotechnology company dealing in the processing and storage of umbilical cord blood stem cells to enable the application of human cells as medicine.

 

At Genzyme, Marc Beer was the Vice President of Global Marketing. He was in charge of commercially launching products aimed at addressing rare disease populations across the world. Marc Beer also worked in sales and marketing while at Abbott Laboratories in the pharmaceutical and diagnostic divisions.

 

Other roles Marc Beer has held in the past include serving on the boards of various companies. At Erytech Pharma, he served as a member of the board of directors while at Good Start genetics he served as the Founding Chairman of the board of directors. He was also the chairman of the compensation committee at Good Start.

 

Marc Beer is currently serving as the Founding Chairman of the board of directors at Minerva Neurosciences Inc. He is also serving in the company’s audit and compensation committees as a member and chairman respectively. Marc Beer also serves on several boards of different universities. Learn more: https://blogwebpedia.com/marc-beer-entrepreneurial-spirit-biotech.html#.XHg3cFNKiqQ

“Marc Beer contributions to women’s health “

Marc beer is the co-founder and CEO of Renovia. He formerly worked as the chief executive officer of the pharmaceuticals known as Algerion; it was a company that dedicated its existence to the developments and commercialization of innovative therapies for patients who are suffering from rare diseases. As the chairman of the organization who has a lot of experience in developing and marketing the enterprises in pharmaceutical and biotechnology field. He has put his effort in bringing up products that will be able to cure urinary incontinence which is a pelvic disorder that has affected over 250 million women all over the world.

Renovia is MedTech company based in Boston that has majored in developing therapeutic products and diagnostic products. The chairman of the organization is working to ensure that the treatment of the patients is technologized. Marc beer collaborated with Ramon Iglesias who is now the managing director of Renovia and Yolanda Lorie back in the year 2016 to form Renovia.

Renovia’s first product to be approved by the food a drug administration was Leva in April 2018. In the course of its life, Renovia received funding which included participation by the Longwood fund wh9ich is an investing organization that lays its focus on health care issues. From all the resources that were infused in the business development and testing of products by Renovia and Beer is aiming for the company to produce a new version of Leva.

Marc beer appreciated the support he got from health care investors. They gave a big helping hand in helping discover the treatment for pelvic floor disorder. People were beginning to understand the cause of pelvic floor disorder will reduce long term health care costs. The organization aims at restoring the health of the pelvic floor. They are putting effort to ensure that the treatment will strengthen the pelvic muscles.

In Renovia they retain records for all their patients to know how to go about treating their patients. The primary vision of the company is to make it possible for their patients to have full control of their body and most importantly the pelvic floor.

Marc beer ended up deciding to form the company due to a lot of interest in the pharmaceutical industry. He realized that there was a need for a company that could take care of this problem that was disturbing most of our women. Marc beer has used his skills and knowledge to the company that is ruling over matters of the health care sector. He has involved himself with a lot of companies to handle the problem of infertility. Marc is in the auditing committee of Minerva neurosciences, and he is also the chair of the committee in charge of compensations. Learn more: https://renoviainc.com/

 

Marc Beer’s Renovia Is Successful In Accumulating Funds For Women-Focused Startup

When it comes related to Biotechnology, Pharmaceuticals, and medically related startups, Marc Beer is not a stranger in developing meaningful products. He is the founder of Renovia, which focuses on finding and developing a cure for pelvic floor disorders that are plaguing women all around the world. Having the knowledge that he acquired in his earlier endeavors in ViaCell, Renovia developed a product called Leva, which is expected to give a revolutionary treatment for patients who have pelvic floor disorders.

 

Leva, which is under Renovia’s wing, is developed to help in diagnosing and treating people will Pelvic Floor Disorders, a condition which is known for being underdiagnosed and undertreated. Anyone can have this condition without knowing it. The Pelvic Floor is the part of the body that contains and support ligaments. tissues and the urinary tract. When things are not going smoothly in here, chances are the patient will develop urinary ailments such as the Urinary Incontinence. Urinary Incontinence is the uncontrolled leakage of urine which affects over 250 million women globally. This also has a lot of undiagnosed cases, just like other Pelvic Floor disorders and is expected to have a higher number because of this.

 

To cure urinary incontinence and other Pelvic Floor Disorders, Leva is being developed to aid in diagnosis and rehabilitation which is aided by modern technological advances such as Bluetooth. The good thing about this treatment and diagnosis is that surgery is not needed to treat the condition reduces the risk of other complications. Leva is among the four products that are being developed by Renovia in order to provide therapy and diagnosis for other diseases.

 

Marc Beer’s endeavors paid off because he and Renovia managed to raise a fund amounting to $32 million via a series B round funding which is made possible by the healthcare-focused investor The Longwood Fund. Another funding of $10 million is made possible through a venture debt. In total, there are $42 million fundings for the development of the four products.

 

In a press conference, Marc Beer thanked the investors who believe in the vision of his company and sent support for the Leva project. Now that the funding is secured, the other three products are planned to be developed. He also promised to make these revolutionary products useful in making techs that will uncover more about the Pelvic Floor Disorders and possibly, other cases in the medical world.

 

Marc Beer is one of the co-founders of Renovia, a firm which drives technology-driven products that improves diagnosis and treatments. He was also the founder of ViaCell, a firm that specializes in the preservation, collection, and development of stem cells from umbilical cord. The firm was acquired by PerkinElmer on 2007. Learn more: https://www.linkedin.com/in/marcbeer